Who will take Korean distribution licenses for Sovaldi and Harvoni?

Published: 2016-10-21 13:33:20

Updated: 2016-10-21 13:33:20

The pharmaceutical distribution industry has shown high interests in the Korean distribution licenses of chronic hepatitis C treatments, ‘Sovaldi’ and ‘Harvoni’ that are indicated as products with extremely low margins, making more deficits as selling them.

This is because the distribution agreement of Gilead Sciences’ ‘Harvoni’ and ‘Sovaldi’ that are exclusively supplied by Zuellig Pharma Kor...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.